DK2208073T3 - Biokemiske markører til cvd-risikovurdering - Google Patents

Biokemiske markører til cvd-risikovurdering Download PDF

Info

Publication number
DK2208073T3
DK2208073T3 DK08847014.1T DK08847014T DK2208073T3 DK 2208073 T3 DK2208073 T3 DK 2208073T3 DK 08847014 T DK08847014 T DK 08847014T DK 2208073 T3 DK2208073 T3 DK 2208073T3
Authority
DK
Denmark
Prior art keywords
risk assessment
biochemical markers
cvd risk
cvd
biochemical
Prior art date
Application number
DK08847014.1T
Other languages
English (en)
Inventor
Morten Karsdal
Natasha Barascuk
Per Qvist
Original Assignee
Nordic Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721713A external-priority patent/GB0721713D0/en
Priority claimed from GB0722748A external-priority patent/GB0722748D0/en
Priority claimed from GB0802814A external-priority patent/GB0802814D0/en
Application filed by Nordic Bioscience As filed Critical Nordic Bioscience As
Application granted granted Critical
Publication of DK2208073T3 publication Critical patent/DK2208073T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08847014.1T 2007-11-05 2008-11-04 Biokemiske markører til cvd-risikovurdering DK2208073T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0721713A GB0721713D0 (en) 2007-11-05 2007-11-05 Biochemical markers of cvd risk
GB0722748A GB0722748D0 (en) 2007-11-20 2007-11-20 Biochemical markers of CVD risk
GB0802814A GB0802814D0 (en) 2008-02-15 2008-02-15 Biochemical markers of CVD risk assessment
PCT/EP2008/064946 WO2009059972A2 (en) 2007-11-05 2008-11-04 Biochemical markers for cvd risk assessment

Publications (1)

Publication Number Publication Date
DK2208073T3 true DK2208073T3 (da) 2020-03-30

Family

ID=40325741

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12185053.1T DK2538222T3 (da) 2007-11-05 2008-11-04 Biokemiske markører til cvd-risikovurdering
DK08847014.1T DK2208073T3 (da) 2007-11-05 2008-11-04 Biokemiske markører til cvd-risikovurdering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12185053.1T DK2538222T3 (da) 2007-11-05 2008-11-04 Biokemiske markører til cvd-risikovurdering

Country Status (7)

Country Link
US (2) US9359633B2 (da)
EP (5) EP2208073B1 (da)
JP (3) JP6039879B2 (da)
CN (3) CN108196072A (da)
DK (2) DK2538222T3 (da)
ES (2) ES2897492T3 (da)
WO (1) WO2009059972A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
ES2897492T3 (es) 2007-11-05 2022-03-01 Nordic Bioscience Imaging As Marcadores bioquímicos para la evaluación de riesgos de CVD
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
EP2770327B1 (en) 2009-03-30 2017-06-14 Nordic Bioscience A/S Fibrosis biomarker assay
FI20095733A0 (fi) * 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
US9465039B2 (en) * 2010-08-06 2016-10-11 Mycartis Nv Perlecan as a biomarker for renal dysfunction
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
GB201107922D0 (en) * 2011-05-12 2011-06-22 Nordic Bioscience As Biochemical markers for CVD risk assessment
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201111788D0 (en) * 2011-07-11 2011-08-24 Nordic Bioscience As In vitro assessment of cardiovascular events by assay for neo-epitopes
CN103987724A (zh) * 2011-11-04 2014-08-13 株式会社日皮 Dpp-4抑制剂
CN102565418A (zh) * 2011-12-25 2012-07-11 复旦大学附属中山医院 一种主动脉疾病早期诊断标志物及其应用
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
EP2810077A2 (de) * 2012-01-30 2014-12-10 mosaiques diagnostics and therapeutics AG Polypeptidmarker zur diagnostik und beurteilung der herzinsuffizienz
EP2834638B1 (en) * 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
WO2013158230A1 (en) * 2012-04-19 2013-10-24 The Regents Of The University Of California Compositions and methods for detecting unstable arteriosclerotic plaques
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
JP6449272B2 (ja) * 2013-07-08 2019-01-09 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． タンパク質の血清半減期を増加する組成物及び方法
GB201400472D0 (en) 2014-01-13 2014-02-26 Nordic Bioscience As Biochemical Markers for pulmonary and other diseases
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US10478130B2 (en) * 2015-02-13 2019-11-19 Siemens Healthcare Gmbh Plaque vulnerability assessment in medical imaging
AU2016366220B2 (en) * 2015-12-10 2021-03-11 Lubrizol Advanced Materials, Inc. Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes
FI127416B (en) * 2016-09-29 2018-05-31 Oy Medix Biochemica Ab Cardiovascular risk assessment method
CN106442979A (zh) * 2016-10-17 2017-02-22 赵军理 一种用于检测肝纤四项的快速定量免疫试纸条
GB201802070D0 (en) * 2018-02-08 2018-03-28 Nordic Bioscience As Elastin assay
JP7547350B2 (ja) 2019-01-22 2024-09-09 クレムソン・ユニバーシティ・リサーチ・ファウンデーション 抗エラスチン抗体及び使用方法
US20250138026A1 (en) * 2022-02-01 2025-05-01 Institut National de la Santé et de la Recherche Médicale Method for diagnosing collagen degradation associated disease
CN116298282B (zh) * 2023-04-21 2025-09-09 新疆维吾尔自治区人民医院 一种检测急性主动脉夹层的生物标志物adamts8及应用
CN117343132B (zh) * 2023-09-25 2024-03-12 山东省农业科学院 一种三文鱼鱼皮来源的ace抑制肽及制备方法
CN119684440B (zh) * 2025-02-25 2025-07-04 深圳柏垠生物科技有限公司 一种重组人源iii型胶原蛋白及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010862A (en) * 1987-11-06 2000-01-04 Washington Research Foundation Methods of detecting collagen type III degradation in vivo
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
FI944575L (fi) * 1992-04-03 1994-11-29 Jolla Cancer Res Found Dekoriinigragmentteja ja menetelmiä solunsäätelytekijöiden inhiboimiseksi
US6703219B1 (en) * 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
DK104093D0 (da) * 1993-09-17 1993-09-17 Osteometer A S Fremgangsmaade til bestemmelse af collagen-fragmenter i legemsvaesker, test-kit og midler til udoevelse af fremgangsmaaden og anvendelse af fremgangsmaaden til diagnosticering af lidelser associeret til collagen-metabolismen
EP0829724A1 (en) * 1996-09-17 1998-03-18 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Assay for detecting collagen degradation
EP0913692A1 (en) * 1997-10-31 1999-05-06 Bayer Ag An immunoassay for procollagen-III-C-terminal propeptide
WO1999061477A2 (en) 1998-05-28 1999-12-02 Bayer Aktiengesellschaft Monoclonal antibody and assay for detecting piiinp
US6916903B2 (en) * 1998-06-19 2005-07-12 Washington Research Foundation Collagen type III synthetic peptides for collagen resorption assays
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
ATE278965T1 (de) * 1999-06-17 2004-10-15 Washington Res Found Knorpelresorptionsassays
JP2002065283A (ja) * 2000-06-12 2002-03-05 Wako Pure Chem Ind Ltd ハイブリッド酵素およびその用途
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
EP1384079A2 (en) * 2001-05-02 2004-01-28 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
GB0112626D0 (en) * 2001-05-23 2001-07-18 Osteometer Biotech As Assay of isomerised and/or optically inverted proteins and protein fragments
WO2003021226A2 (en) * 2001-08-31 2003-03-13 Pharmacia Corporation Peptide biomarker and method of identification
WO2003040691A2 (en) * 2001-11-05 2003-05-15 The Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
EP1496886A1 (en) * 2002-04-12 2005-01-19 Cartela AB Knockout mice and their use
CN1874792A (zh) * 2003-09-03 2006-12-06 布里斯托尔-迈尔斯.斯奎布制药公司 包含基质金属蛋白酶底物的化合物及其使用方法
US20050255491A1 (en) * 2003-11-13 2005-11-17 Lee Frank D Small molecule and peptide arrays and uses thereof
US20060154318A1 (en) * 2004-06-09 2006-07-13 Anderson Norman L Stable isotope labeled polypeptide standards for protein quantitation
EP1948686A4 (en) * 2005-10-26 2009-06-10 Stc Unm C-REACTIVE PROTEIN AND ITS USE FOR THE TREATMENT OF SYSTEMIC LUPUSERYTHEMATODES AND RELATED SUFFERINGS
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
KR20080078675A (ko) * 2005-12-22 2008-08-27 시오노기 앤드 컴파니, 리미티드 급성 관상동맥 증후군의 예후 예측 방법
ES2897492T3 (es) * 2007-11-05 2022-03-01 Nordic Bioscience Imaging As Marcadores bioquímicos para la evaluación de riesgos de CVD
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
EP2770327B1 (en) * 2009-03-30 2017-06-14 Nordic Bioscience A/S Fibrosis biomarker assay
GB201107922D0 (en) * 2011-05-12 2011-06-22 Nordic Bioscience As Biochemical markers for CVD risk assessment
CN103703370B (zh) * 2011-05-27 2016-08-17 北欧生物科技公司 诊断性肽的检测
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201111788D0 (en) * 2011-07-11 2011-08-24 Nordic Bioscience As In vitro assessment of cardiovascular events by assay for neo-epitopes

Also Published As

Publication number Publication date
CN108196072A (zh) 2018-06-22
EP2538222A3 (en) 2013-04-24
US10267809B2 (en) 2019-04-23
EP2538223A3 (en) 2013-04-24
JP6039879B2 (ja) 2016-12-07
EP2538223A8 (en) 2013-02-27
EP2538218A3 (en) 2013-04-24
CN105510601A (zh) 2016-04-20
EP2538218A2 (en) 2012-12-26
EP2538218A8 (en) 2013-02-27
US20160282362A1 (en) 2016-09-29
EP2538221A2 (en) 2012-12-26
EP2538221A3 (en) 2013-04-24
EP2208073B1 (en) 2020-01-15
WO2009059972A2 (en) 2009-05-14
WO2009059972A3 (en) 2009-09-17
CN105510601B (zh) 2018-04-10
JP2011503564A (ja) 2011-01-27
EP2538223A2 (en) 2012-12-26
EP2538222A8 (en) 2013-02-27
CN101918846A (zh) 2010-12-15
US20100323377A1 (en) 2010-12-23
US9359633B2 (en) 2016-06-07
JP6309669B2 (ja) 2018-04-11
EP2538222B1 (en) 2021-08-25
EP2208073A2 (en) 2010-07-21
ES2897492T3 (es) 2022-03-01
JP2017181509A (ja) 2017-10-05
DK2538222T3 (da) 2021-11-15
EP2538222A2 (en) 2012-12-26
ES2777948T3 (es) 2020-08-06
JP2015007638A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
DK2208073T3 (da) Biokemiske markører til cvd-risikovurdering
DK2173917T3 (da) Stål til sure servicemiljøer
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0814797A2 (pt) Inibidores dna-pk
KR101541791B9 (ko) 다형태
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
BRPI0820020A2 (pt) Material anticorrosão
EP2233838A4 (en) COOKER
EP2115162A4 (en) Adrb2 cancer markers
PL2156076T3 (pl) Zawory
DK2310613T3 (da) Forbedret brudled til stigrør
EP2156167A4 (en) BIOCHIP
BRPI0814411A2 (pt) Compostos químicos
DK2225149T3 (da) Tætning til finnefremdrift
BRPI0808129A2 (pt) Compostos químicos
EP2115333A4 (en) VALVE
DK2069093T3 (da) Nedholder til pladesakse
FI20075688L (fi) Jauhin
FR2924101B1 (fr) Valve amelioree
DK2165040T3 (da) Forbedret indgrebssystem til borebrønd
FI20070090A0 (fi) Lattialämmitystermostaatti
EP2154259A4 (en) CERMET
SE0801340L (sv) Fixeringsverktyg
FI7125U1 (fi) Huoltotaso
ES1063619Y (es) Tuberia compensada